Citadel Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,900
| Closed | -$1.02K | – | 16039 |
|
|
2024
Q4 | $1.02K | Sell |
1,900
-32,600
| -94% | -$22.7K | ﹤0.01% | 14239 |
|
|
2024
Q3 | $60.7K | Sell |
34,500
-39,200
| -53% | -$54.7K | ﹤0.01% | 11691 |
|
|
2024
Q2 | $86.2K | Buy |
73,700
+35,400
| +92% | +$88.6K | ﹤0.01% | 11118 |
|
|
2024
Q1 | $346K | Sell |
38,300
-67,000
| -64% | -$651K | ﹤0.01% | 9165 |
|
|
2023
Q4 | $1.14M | Sell |
105,300
-13,000
| -11% | -$97.4K | ﹤0.01% | 6417 |
|
|
2023
Q3 | $952K | Buy |
118,300
+61,200
| +107% | +$509K | ﹤0.01% | 6654 |
|
|
2023
Q2 | $620K | Buy |
57,100
+11,600
| +25% | +$99.3K | ﹤0.01% | 7461 |
|
|
2023
Q1 | $314K | Buy |
45,500
+29,600
| +186% | +$186K | ﹤0.01% | 9289 |
|
|
2022
Q4 | $63.3K | Sell |
15,900
-2,600
| -14% | -$12.8K | ﹤0.01% | 11847 |
|
|
2022
Q3 | $123K | Buy |
18,500
+1,750
| +10% | +$10.8K | ﹤0.01% | 10914 |
|
|
2022
Q2 | $81K | Sell |
16,750
-69,500
| -81% | -$423K | ﹤0.01% | 11588 |
|
|
2022
Q1 | $806K | Buy |
86,250
+17,225
| +25% | +$171K | ﹤0.01% | 8206 |
|
|
2021
Q4 | $820K | Buy |
69,025
+5,100
| +8% | +$58.9K | ﹤0.01% | 8430 |
|
|
2021
Q3 | $727K | Sell |
63,925
-14,475
| -18% | -$199K | ﹤0.01% | 8965 |
|
|
2021
Q2 | $1.41M | Sell |
78,400
-14,500
| -16% | -$233K | ﹤0.01% | 7457 |
|
|
2021
Q1 | $1.44M | Sell |
92,900
-31,300
| -25% | -$453K | ﹤0.01% | 7210 |
|
|
2020
Q4 | $1.51M | Buy |
+124,200
| New | +$1.73M | ﹤0.01% | 5954 |
|
|
2020
Q3 | – | Sell |
-8,275
| Closed | -$84K | – | 10916 |
|
|
2020
Q2 | $84K | Buy |
8,275
+2,100
| +34% | +$19.3K | ﹤0.01% | 9087 |
|
|
2020
Q1 | $50K | Sell |
6,175
-5,850
| -49% | -$50.7K | ﹤0.01% | 9032 |
|
|
2019
Q4 | $104K | Buy |
12,025
+4,600
| +62% | +$25.8K | ﹤0.01% | 8532 |
|
|
2019
Q3 | $46K | Sell |
7,425
-113,325
| -94% | -$916K | ﹤0.01% | 8730 |
|
|
2019
Q2 | $2M | Buy |
120,750
+111,025
| +1,142% | +$1.93M | ﹤0.01% | 4506 |
|
|
2019
Q1 | $163K | Sell |
9,725
-40,200
| -81% | -$579K | ﹤0.01% | 8345 |
|
|
2018
Q4 | $573K | Buy |
49,925
+27,425
| +122% | +$555K | ﹤0.01% | 6202 |
|
|
2018
Q3 | $900K | Buy |
22,500
+7,425
| +49% | +$211K | ﹤0.01% | 5729 |
|
|
2018
Q2 | $426K | Buy |
15,075
+11,000
| +270% | +$244K | ﹤0.01% | 6638 |
|
|
2018
Q1 | $62K | Buy |
+4,075
| New | +$97K | ﹤0.01% | 7864 |
|
Citadel Advisors's MRNS Position: Q1 2025 in Review
Citadel Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 501,911 shares — an estimated $269K sold.
Citadel Advisors first reported a position in MRNS in Q1 2017 and held it in 31 quarters. The position peaked at $11.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Citadel Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 501,911 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $269K.
- Citadel Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q1 2017 and held it in 31 quarters.
- Citadel Advisors's Marinus Pharmaceuticals, Inc position peaked at $11.2M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.